An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GoodRx Teams Up with AssistRx to Increase Provider Awareness of Simplified Specialty Medication and Treatment Initiation
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
GoodRx (GDRX) announces a collaboration with AssistRx to enhance access to specialty medication therapy and streamline medication initiation. This partnership aims to address delays in patient care caused by prior authorization processes, which currently average 14-20 days. With 93% of physicians reporting care delays due to such requirements, GoodRx intends to leverage its provider network to promote AssistRx's iAssist platform, facilitating real-time access to patient benefits and prior authorization information. The collaboration reflects GoodRx's commitment to improving healthcare efficiency and affordability.
Positive
Partnership with AssistRx aimed at reducing delays in specialty medication therapy initiation.
GoodRx leverages its extensive provider network to enhance awareness of the iAssist platform.
The collaboration aims to improve healthcare access and affordability.
Negative
The average delay for specialty therapy initiation remains high at 14-20 days.
93% of physicians report care delays due to prior authorization requirements.
The collaboration will provide physicians with improved access to speciality therapy and medication initiation solutions
SANTA MONICA, Calif.--(BUSINESS WIRE)--
GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced a new effort with AssistRx to bring broader awareness and access to branded and specialty medication therapy initiation. GoodRx will leverage its large provider reach to drive attention to AssistRx’s iAssist platform, which gives providers immediate access to a patient’s coverage, improved price transparency and the right prior authorization information.
Specialty therapy initiation, or the seemingly simple task of prescribing medication and treating a patient, can be an arduous process due to complex enrollment, step-edits and prior authorization requirements, with the industry standard for patient specialty therapy initiation averaging 14-20 days. What’s more, according to a 2021 survey from the American Medical Association, 93% of practicing physicians reported delays in care due to prior authorizations, and over 82% reported prior authorization led to treatment abandonment entirely. The new collaboration between GoodRx and AssistRx aims to reduce treatment delays by supporting provider awareness of the benefits of the iAssist platform and the automated, real-time information they need to initiate treatment.
“At GoodRx, we’re continuously seeking out new ways to make healthcare providers’ work easier and help eliminate the barriers many physicians face when connecting patients with the right treatment,” said Doug Hirsch, co-CEO and co-founder of GoodRx. “This new relationship with AssistRx will help providers know where to go when working through therapy initiation obstacles related to access, affordability, cost, and enrollment, ensuring more patients will be able to get the care they need, when they need it.”
AssistRx provides one of the most comprehensive specialty therapy initiation solutions in the industry, allowing healthcare providers to utilize the iAssist platform to reduce therapy delays for patients. They do this by powering provider offices with access to real-time patient and product-specific benefit information, as well as e-prescribing and manufacturer support services e-enrollment. GoodRx expects this collaboration to further deliver on its vision of making healthcare affordable and convenient for all Americans.
“Working with GoodRx supports our vision to transform lives through improved access to therapy,” said Jeff Spafford, CEO of AssistRx. “Through this work, we will be able to deliver our comprehensive therapy initiation solution, iAssist, to more healthcare providers across all specialties and, in the end, shorten the amount of time that it takes for a patient to get on the medication they need.”
About GoodRx
GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $35 billion and are one of the most downloaded medical apps over the past decade.
About AssistRx
AssistRx has engineered the perfect blend of technology and talent to provide manufacturers with an intelligent therapy initiation and patient support solution to improve patient uptake, visibility and outcomes. Our solution integrates technology and therapy expertise to advance patient therapy in a more efficient and effective manner—delivering informed touchpoints that simplify a complex system to enable better results for today’s patients. For more information, visit www.assistrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the benefits of a collaboration between GoodRx and AssistRx. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our acquisition strategy, the integration of acquired business and the important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
GoodRx's new collaboration with AssistRx aims to enhance access to specialty medication therapy and streamline the initiation process for medications.
How does the iAssist platform improve medication initiation for patients?
The iAssist platform provides healthcare providers with real-time access to patient coverage, price transparency, and prior authorization information, aiming to reduce the time it takes to start treatments.
What issues does the GoodRx and AssistRx partnership address?
The partnership addresses significant delays in patient care caused by complex prior authorization processes, which can average 14-20 days.
How does GoodRx plan to promote the iAssist platform?
GoodRx plans to leverage its extensive provider reach to increase awareness and utilization of the iAssist platform among healthcare providers.
What are the expected outcomes of the GoodRx and AssistRx collaboration?
The collaboration is expected to shorten the time it takes for patients to receive necessary medications and improve healthcare efficiency.
